PAVmed says it is engaged with FDA on Portio and Octeris
PAVM•PAVmed said it is engaged with the FDA on Portio and Octeris and had $8.9 million in cash and cash equivalents, including $5.3 million in restricted cash, as of September 30, 2026.
1. FDA engagement and cash
PAVmed said it is engaged with the FDA on Portio and Octeris. The company reported cash and cash equivalents of $8.9 million, including restricted cash of $5.3 million, as of September 30, 2026.
